Mayo Clinic Platform

AccurKardia is an ECG-led diagnostics software company dedicated to enhancing the utility of ECG data as a diagnostic tool and biomarker to improve patient outcomes globally. The company specializes in cloud-based diagnostic solutions, including AccurECG™, an FDA-cleared software that provides fully automated, near real-time ECG interpretation. Additionally, AccurKardia developed AK+ Guard™, an AI-driven solution designed to detect hyperkalemia using Lead I ECG data, which aids patients with chronic kidney disease and end-stage renal disease in identifying dangerously high potassium levels at an earlier stage; this product has received FDA Breakthrough Device Designation. The company's aortic stenosis detection model, AK-AVS™, also received similar recognition. AccurKardia participated in the 2024 Cohort of MedTech Innovator and was selected for the inaugural American Heart Association's Heart and Brain Health Accelerator track, further emphasizing its commitment to advancing cardiac diagnostics and monitoring.

Saigeware Technologies, founded in 2020 and headquartered in Karnataka, India, specializes in delivering actionable insights in the healthcare sector. The company develops an AI-based platform aimed at supporting evidence-based medicine specifically in cardiac and pulmonary practices. Its services encompass telemedicine, drug discovery, and the design of original equipment manufacturers (OEMs), as well as personal wellness applications. Through these offerings, Saigeware empowers both doctors and patients by providing valuable insights into various health issues, enhancing the overall quality of care.

SOAP Health is a healthcare technology company founded in 2019 and based in Boca Raton, Florida. It specializes in developing an artificial intelligence-driven platform that enhances clinical decision-making by capturing and analyzing detailed patient data prior to medical visits. The platform facilitates accurate and efficient patient-reported data collection, risk assessment, and documentation, resulting in a 90% completed SOAP Note for physicians. This system aims to improve patient care and doctor productivity while reducing liability exposure. Additionally, SOAP Health's conversational AI interface integrates with electronic health records to assess risk factors and engage patients effectively, enabling healthcare providers to identify at-risk individuals and promote early disease detection and intervention.

Biotia, Inc. is a health technology company based in New York, founded in 2016. It specializes in developing software and laboratory technologies that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery and management. By providing tailored microbial surveillance, Biotia's innovative solutions enable clinicians and researchers to identify and mitigate pathogens effectively, thereby reducing hospital-acquired infections and improving patient outcomes. The company's technology empowers healthcare professionals to guide treatment decisions proactively, ultimately aiming to prevent illnesses before they occur.

Dynocardia, Inc. is a biomedical device company focused on developing innovative healthcare solutions. Founded in 2018 and based in Cambridge, Massachusetts, Dynocardia specializes in manufacturing wireless blood pressure measurement equipment. Its flagship product, the ViTrack, is a wrist-wearable device that provides users with accurate, real-time measurements of blood pressure, heart rate, heart rhythm, and respiration rate. The technology employs a non-invasive optomechanical sensor to deliver continuous and precise blood pressure readings, comparable to traditional intra-arterial methods. By addressing critical unmet needs in health monitoring, Dynocardia aims to enhance patient care and facilitate easier access to vital health metrics.

Delfina operates a data-driven prenatal care system designed to enhance maternal and infant safety during pregnancy. The company employs machine learning models to optimize interventional workflows and create personalized care plans based on patient risk factors, thereby facilitating early interventions and improving provider efficiency. This approach aims to deliver equitable and cost-effective pregnancy care within the healthcare industry.

ImpriMed, Inc. is a biotechnology company focused on providing personalized drug response prediction services for veterinary oncology. Established in 2017 and headquartered in Palo Alto, California, with an additional office in Seoul, South Korea, the company specializes in analyzing the drug responses of live cancer cells from pets, particularly in cases of lymphoma. By collecting genetic and cellular information from these cancer cells, ImpriMed develops precision medicine techniques that assist veterinary oncologists in selecting the most effective anticancer treatments for individual pets. This patient-derived database not only enhances treatment decisions for animals but also has the potential to translate insights into human oncology, ultimately aiding in the development of tailored cancer therapies for humans.